Mariana Rodrigues Pioli1, Ana Paula de Faria2. 1. Department of Pharmacology, FCM 10 Building, School of Medical Sciences - University of Campinas (FCM-UNICAMP), Tessália Vieira de Camargo, 126, Campinas, SP, 13083-970, Brazil. 2. Department of Pharmacology, FCM 10 Building, School of Medical Sciences - University of Campinas (FCM-UNICAMP), Tessália Vieira de Camargo, 126, Campinas, SP, 13083-970, Brazil. ana.cabralfaria@gmail.com.
Abstract
PURPOSE OF REVIEW: To gather data from studies evaluating the pro-inflammatory profile of individuals with resistant hypertension (RH), and bring a clinical update of new and potential complementary therapies to treat inflammation in RH. RECENT FINDINGS: Increases in pro-inflammatory cytokines are related to elevated blood pressure and target organ damage in RH patients. Clinical and experimental studies have shown that some biological therapies, especially TNF-α inhibitors, regulated pro- and anti-inflammatory cytokines associated with improvements in clinical outcomes, although they are not yet reported in RH. New emerging therapies to treat inflammation in RH, although promising, are still hypotheses that have not been scientifically confirmed in clinical trials. For this reason, inflammation-target treatments, such as the TNF-α and IL-6 inhibitors, should be encouraged for testing as complementary therapies in RH in order to elucidate their potential benefits.
PURPOSE OF REVIEW: To gather data from studies evaluating the pro-inflammatory profile of individuals with resistant hypertension (RH), and bring a clinical update of new and potential complementary therapies to treat inflammation in RH. RECENT FINDINGS: Increases in pro-inflammatory cytokines are related to elevated blood pressure and target organ damage in RH patients. Clinical and experimental studies have shown that some biological therapies, especially TNF-α inhibitors, regulated pro- and anti-inflammatory cytokines associated with improvements in clinical outcomes, although they are not yet reported in RH. New emerging therapies to treat inflammation in RH, although promising, are still hypotheses that have not been scientifically confirmed in clinical trials. For this reason, inflammation-target treatments, such as the TNF-α and IL-6 inhibitors, should be encouraged for testing as complementary therapies in RH in order to elucidate their potential benefits.
Authors: Aly M Abdelrahman; Yousuf M Al Suleimani; Mohammed Ashique; Priyadarsini Manoj; Badreldin H Ali Journal: Biomed Pharmacother Date: 2018-05-29 Impact factor: 6.529
Authors: Naomi B Klarenbeek; Sjoerd M van der Kooij; Tineke J W Huizinga; Yvonne P M Goekoop-Ruiterman; Harry M J Hulsmans; Michiel V van Krugten; Irene Speyer; Jeska K de Vries-Bouwstra; Pit J S M Kerstens; Tom W J Huizinga; Ben A C Dijkmans; Cornelia F Allaart Journal: Ann Rheum Dis Date: 2010-05-14 Impact factor: 19.103
Authors: S M Krishnan; J K Dowling; Y H Ling; H Diep; C T Chan; D Ferens; M M Kett; A Pinar; C S Samuel; A Vinh; T V Arumugam; T D Hewitson; B K Kemp-Harper; A A B Robertson; M A Cooper; E Latz; A Mansell; C G Sobey; G R Drummond Journal: Br J Pharmacol Date: 2015-07-31 Impact factor: 8.739
Authors: Ademir Gazzoto Filho; Andrezza Kinote; Daniel J Pereira; André Rennó; Rodrigo C dos Santos; Silvia E Ferreira-Melo; Licio A Velloso; Silvana Bordin; Gabriel F Anhê; Heitor Moreno Junior Journal: Eur J Pharmacol Date: 2012-12-07 Impact factor: 4.432
Authors: Meena S Madhur; Heinrich E Lob; Louise A McCann; Yoichiro Iwakura; Yelena Blinder; Tomasz J Guzik; David G Harrison Journal: Hypertension Date: 2009-12-28 Impact factor: 10.190
Authors: Frank M Schmidt; Julia Weschenfelder; Christian Sander; Juliane Minkwitz; Julia Thormann; Tobias Chittka; Roland Mergl; Kenneth C Kirkby; Mathias Faßhauer; Michael Stumvoll; Lesca M Holdt; Daniel Teupser; Ulrich Hegerl; Hubertus Himmerich Journal: PLoS One Date: 2015-03-17 Impact factor: 3.240
Authors: Helen M McGettrick; Samuel J E Lucas; Samuel R C Weaver; Catarina Rendeiro; Rebekah A I Lucas; N Timothy Cable; Tom E Nightingale Journal: Eur J Appl Physiol Date: 2022-09-23 Impact factor: 3.346
Authors: Alana Aragón-Herrera; Sandra Feijóo-Bandín; Laura Anido-Varela; Sandra Moraña-Fernández; Esther Roselló-Lletí; Manuel Portolés; Estefanía Tarazón; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago Journal: J Pers Med Date: 2022-06-21
Authors: Days O Andrade; Franciana L Aguiar; Ana Luiza P Mansor; Flavia M Valente; Doroteia R S Souza; Valquiria da Silva Lopes; Leticia B Fernandes; Moacir F Godoy; Juan C Yugar-Toledo; Luciana N Cosenso-Martin; Jose F Vilela-Martin Journal: Front Cardiovasc Med Date: 2022-09-29